Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

RANGE study investigators

Research output: Contribution to journalArticlepeer-review

100 Scopus citations

Fingerprint Dive into the research topics of 'Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences